3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL) - Chavez, JC; Dickinson, M; Munoz, JL (Blood, 2023)
et al.